Kranten1 l.r..jpg

N E W S 

8 September 2022

Neuroplast receives second orphan medicinal product designation for Neuro-Cells®, paving the way for application to both chronic and trauma-induced neurodegenerative diseases.

Read more

 

23 June 2022

What causes complications after stroke and how to prevent them? The department of neurosurgery of Maastricht University Medical Centre+ and clinical stage biotech Neuroplast start research on factors that cause delayed cerebral ischemia after subarachnoid hemorrhage.

Read more

 

21 June 2022

Why Stem Cell Technology for Neurodegenerative Diseases Requires a Paradigm Shift.

This article is taken from European Biopharmaceutical Review July 2022, pages 44-46. © Samedan Ltd

Read more

 

20 April 2022

New lab facility gives growing Neuroplast production independence and accelerates clinical pipeline expansion.

Read more

29 March 2022

Stem cell biotech Neuroplast enrolls first patient in Phase II clinical trial of transformative Neuro-Cells® treatment for Traumatic Spinal Cord Injury. 

Read more

 

04 February 2022

Stem cell biotech Neuroplast has opened a second facility in Maastricht, the Netherlands. 

Read more

 

17 November 2021

Dutch stem cell biotech Neuroplast secures € 10 million (US$ 11.5 million) in Series B funding to further advance its transformative stem cell therapy for Traumatic Spinal Cord Injury.

Read more

09 November 2021

Dutch stem cell biotech Neuroplast announces successful clinical Phase I trial with its Neuro-Cells® stem cell treatment for Traumatic Spinal Cord Injury.

Read more

 

21 October 2021

Dutch stem cell biotech Neuroplast appoints TiGenix founder Frank Luyten and Sanquin director Pieter
de Geus to its supervisory board.

Read more

 

19 November 2020

Neuro-Cells® in patient. Neuroplast BV announced the first patient with chronic spinal cord injury was treated with Neuro-Cells®.

Read more
 

18 February 2020

Neuroplast raises € 4 million for its stem cell-based technology to treat patients with Spinal Cord Injury. 

Read more

01 May 2019

European Medicines Agency (EMA) has granted Orphan Drug Designation to Neuroplast treatment. 

Read more